Navigation Links
Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
Date:1/22/2008

identifying and licensing clinically enabled compounds like rufinamide allows Synosia to quickly move into smart, efficient clinical trials designed to rapidly establish proof of concept in new therapeutic areas," said Synosia Chief Executive Officer and President Ian Massey. "Rufinamide, a structurally novel compound with proven efficacy in epilepsy and with an extensive safety database, was a perfect candidate to demonstrate the soundness of our strategy. The impressive speed in which this trial was designed, executed and completed is a real highlight for us."

About Rufinamide

The drug was originally discovered and developed by Novartis, which granted certain licensing rights to Eisai of Japan in 2004. In January 2007, Eisai received marketing authorisation in the European Union for Inovelon(R) (rufinamide) as adjunctive anti-epileptic therapy in Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy that develops in early childhood. Eisai has also submitted an NDA for rufinamide to the US Food and Drug Administration (FDA) for adjunctive therapy in adults and adolescents. The extensive clinical development program for rufinamide in epilepsy has generated over 2500 patient-years of exposure to the drug.

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialise innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company is developing six clinical-stage compounds acquired through key partnerships with Novartis, Roche and Syngenta, including two marketed drugs that will be tested in new indications, extending their reach into new therapeutic areas with combined sales potential in excess of US$2.5 billion. Synosia has offices in Basel, Switzerland, and South San Francisco, CA.

Synosia Therapeutics has raised US$32.5 million funding from Versant Ventures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures (Menlo Park, CA) a
'/>"/>

SOURCE Synosia Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synosia Therapeutics Announces Appointment of Chief Business Officer
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Green & Grow Inc. (GGI) has raised ... secured Otter Capital as a significant new partner. Otter ... GGI’s Agriplier™ technology, building on recent compelling field trial ... first meeting, we have been impressed with Otter Capital’s ... Alan Sobba, President and CEO of GGI. “We look ...
(Date:8/27/2014)... California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security LLC ... to develop and deliver a state-of-the-art laser system ... facility (ELI Beamlines), under construction in the Czech ... performance, the laser system, called the " High ...
(Date:8/27/2014)... DENVER , Aug. 27, 2014   MSC ... and patient safety, today announced the appointment of ... With 28 years of experience preparing companies ... in 2013 as Executive Vice President of Corporate Development ... healthcare performance improvement business , as well as corporate ...
(Date:8/27/2014)... 27, 2014 The Global and China ... on the current state of the Trifluoroacetic Acid industry ... basic overview of the industry, including definitions, applications and ... market analysis are provided with a focus on history, ... comparison between the international and Chinese situation is also ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... EMERYVILLE, Calif., Oct. 10 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... call on Monday, October 13, to provide an update ... ischemic stroke.,Hosting the call will be Paul E. Freiman, ... medical officer., -- Date: Monday, October 13, ...
... CSMG,Technologies, Inc., (OTC Bulletin Board: CTGI), ... received approval of its fifth U.S.,patent. The ... for "Bonding of,Soft Biological Tissues by Passing ... subsidiary Live Tissue Connects ("LTC"),platform tissue bonding/welding ...
... Calif., Oct. 10 Finesse Solutions, LLC, a,manufacturer ... process,applications, is pleased to announce improvements to their ... even easier. The E-Store,can be found at the ... easily purchase bioprocess sensors and accessories,on-line, anywhere in ...
Cached Biology Technology:Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 3
(Date:8/28/2014)... Researchers at the University of Minnesota have developed an ... be used for muscle regeneration research as well as ... , The research is published in the current edition ... is no treatment for FSHD, which is thought by ... dystrophy. FSHD is an unusual genetic disorder because, unlike ...
(Date:8/28/2014)... A unique method for delivering compounds that ... HIV and AIDS may be possible, thanks ... Agricultural Sciences., A semi-soft vaginal suppository made ... loaded with the antiviral drug Tenofovir provides ... against the spread of sexually transmitted infections ...
(Date:8/28/2014)... More than 25 million kilometres of new roads will ... will slice into Earth,s last wildernesses, where they bring ... , Now, an ambitious study has created a ... to try to balance the competing demands of development ... an ,environmental-values, layer that estimates that natural importance of ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... Durham University have discovered a natural mechanism in plants that ... to better crop yields. Plants naturally slow their growth ... such as water shortage or high salt content in soil, ... making proteins that repress the growth of the plant. This ...
... vehicles that have fish-like sensations, advanced ship design and ... Research (ONR) on Dec. 23 learned they will receive ... The researchers have been selected for Presidential Early ... be honored at a ceremony at the White House ...
... genetic signature that implicates a key mechanism in the immune ... leukaemia. Acute lymphoblastic leukaemia or ALL is the most ... leukaemia for one in four ALL patients is a mutation ... fuse together. This genomic alteration happens before birth and kick ...
Cached Biology News:New discovery could stimulate plant growth and increase crop yields, researchers say 2White House lauds ONR-funded researchers for early success 2Immune system development linked to leukemia 2Immune system development linked to leukemia 3
... cells (BTI-TN-5B1-4) derived from Trichoplusia ni ... to be capable of expressing significantly ... compared to other insect cells. High ... doubling time as adherent cultures- Quick adaptation ...
... steadylite plus assay system offers ... sensitivity, Designed for batch-processing systems, ... higher density microplates such as ... free, Convenient storage conditions ( ...
... lysis buffer, PCR mix, DNA polymerase and ... volume PCR reactions. This system can detect ... rod and coccus bacteria, such as Escherichia ... Streptococcus Agalactiae, and etc. With the powerful ...
... Kit is uniquely formulated to give ... protein modification for optimal mass spectrometry ... with traditional silver stains are eliminated ... reagents used do not modify protein ...
Biology Products: